Back Hepatitis B

Hepatitis B

EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity

NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.

alt

Read more:

EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys

The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on bone and kidney biomarkers, according to a pair of studies presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

Read more:

Survey Shows More than 800,000 in U.S. Have Hepatitis B, Half of Them Asian

Although nearly 70 million people in the U.S. have been vaccinated against hepatitis B virus (HBV), there are still 847,000 people with evidence of infection, about 400,000 of whom are Asian, according to the latest NHANES survey results published in the February edition of Hepatology.

alt

Read more:

Hepatitis B and C Transmission Could Be Ended in the U.S., Report Says

Hepatitis B and C could be eliminated as a public health threat in the U.S. by treating more people in order to end transmission and prevent progression of liver disease and death, according to a new report from the National Academies of Sciences, Engineering, and Medicine (formerly the Institute of Medicine).

alt

Read more:

Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer

Widespread vaccination against hepatitis B virus (HBV) and prompt treatment of chronic hepatitis C virus (HCV) -- which together are the most common cause of hepatocellular carcinoma -- could prevent an estimated 80% of liver cancer deaths, according to the World Hepatitis Alliance in an announcement commemorating World Cancer Day.

alt

Read more:

Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C

Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.

alt

Read more:

Latino Adults Have Hepatitis B Rates Similar to the General U.S. Population

Hispanic and Latino adults living in the U.S. are about as likely as the general population to have active hepatitis B virus (HBV) infection, though rates varied across subgroups based on country of origin, according to research published in the February edition of Hepatology.

alt

Read more:

CROI 2016: Injection-Related Indiana HIV Epidemic Is Under Control, But Vigilance Needed

Extensive epidemiological investigation followed by prevention and treatment interventions have largely succeeded in controlling an outbreak of HIV and hepatitis C virus (HCV) infection in rural Indiana linked to injection of prescription opioids, but new cases continue to appear and many other communities may be at risk for similar outbreaks, according to presentations at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston.

alt

Read more:

AASLD 2015: Hepatitis B Core Inhibitor NVR 3-778 Inhibits Viral Replication

Novira Therapeutics' NVR 3-778, a novel drug that interferes with the hepatitis B virus (HBV) core protein, blocked replication of various types of HBV in a laboratory study and reduced HBV viral load with no apparent safety issues in an early human trial, researchers reported at the AASLD Liver Meeting in November.

alt

Read more: